EyePoint Pharmaceuticals, Inc. (EYPT): Price and Financial Metrics

EyePoint Pharmaceuticals, Inc. (EYPT): $8.47

0.31 (+3.80%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

C

EYPT Price/Volume Stats

Current price $8.47 52-week high $30.99
Prev. close $8.16 52-week low $5.67
Day low $7.95 Volume 1,114,400
Day high $8.55 Avg. volume 1,089,147
50-day MA $13.44 Dividend yield N/A
200-day MA $16.11 Market Cap 441.15M

EYPT Stock Price Chart Interactive Chart >


EyePoint Pharmaceuticals, Inc. (EYPT) Company Bio


EyePoint Pharmaceuticals (formerly pSivida Corp.) develops sustained-release drug-delivery products for treating eye diseases in the United States and the United Kingdom. It offers ILUVIEN, an injectable, sustained-release micro-insert for use in treating vision impairment associated with diabetic macular edema; and Retisert for the treatment of posterior uveitis. The company was founded in 1987 and is based in Watertown, Massachusetts.


EYPT Latest News Stream


Event/Time News Detail
Loading, please wait...

EYPT Latest Social Stream


Loading social stream, please wait...

View Full EYPT Social Stream

Latest EYPT News From Around the Web

Below are the latest news stories about EYEPOINT PHARMACEUTICALS INC that investors may wish to consider to help them evaluate EYPT as an investment opportunity.

EyePoint Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

WATERTOWN, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint Pharmaceuticals will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2024 at 10:30 a.m. PT/1:30 p.m. ET. A webcast and subs

Yahoo | December 20, 2023

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregat

Yahoo | December 18, 2023

What EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) 194% Share Price Gain Is Not Telling You

EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) shareholders would be excited to see that the share price has had a...

Yahoo | December 18, 2023

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Analysts Just Trimmed Their Revenue Forecasts By 11%

Market forces rained on the parade of EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) shareholders today, when the...

Yahoo | December 13, 2023

EyePoint Pharmaceuticals (EYPT) is a Great Momentum Stock: Should You Buy?

Does EyePoint Pharmaceuticals (EYPT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Yahoo | December 11, 2023

Read More 'EYPT' Stories Here

EYPT Price Returns

1-mo -23.76%
3-mo -61.95%
6-mo N/A
1-year 25.11%
3-year -11.77%
5-year -45.00%
YTD -63.35%
2023 560.29%
2022 -71.41%
2021 86.02%
2020 -57.55%
2019 -17.99%

Continue Researching EYPT

Here are a few links from around the web to help you further your research on EyePoint Pharmaceuticals Inc's stock as an investment opportunity:

EyePoint Pharmaceuticals Inc (EYPT) Stock Price | Nasdaq
EyePoint Pharmaceuticals Inc (EYPT) Stock Quote, History and News - Yahoo Finance
EyePoint Pharmaceuticals Inc (EYPT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!